NCT00993642 |
|
ERB-B4 After Treatment With HDAC Inhibitor in ER Tamoxifen Refractory Breast Cancer
|
View
|
NCT01421446 |
|
Study to Validate a Computerized Neuropsychological Test Battery
|
View
|
NCT01136499 |
|
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure
|
View
|
NCT01222936 |
|
LBH Phase II in Small Cell Lung Cancer SCLC
|
View
|
NCT00419536 |
|
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
|
View
|
NCT01582009 |
|
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
|
View
|
NCT02032810 |
|
Phase I of Histone Deacetylase HDAC Inhibitor Panobinostat With Ipilimumab With Unresectable IIIIV Melanoma
|
View
|
NCT01090973 |
|
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia CLL and Mantle Cell Lymphoma MCL
|
View
|
NCT06267430 |
|
Learning by Heart The Effectiveness of an EF Training Program for Pre-schoolers With a Severe CHD
|
View
|
NCT01282476 |
|
Panobinostat With Rituximab for RelapsedRefractory Diffuse Large B Cell Lymphoma
|
View
|
NCT02070068 |
|
A Pilot Dosing and Timing Study to Optimize Imaging When Utilizing Endoscopic Fluorescence Imaging System During Laparoscopic Biliary and Hepatic Operations
|
View
|
NCT01194908 |
|
Re-expression of ER in Triple Negative Breast Cancers
|
View
|